Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 11Lymphoma, Non-Hodgkin 9Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Myelodysplastic Syndromes 4Neoplasms, Plasma Cell 3Melanoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Glioma 3Primary Myelofibrosis 2Myeloproliferative Disorders 2Lymphoma, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Wilms Tumor 1Sarcoma 1Recurrence 1Philadelphia Chromosome 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lung Neoplasms 1

Interventions

Dexamethasone 49Melphalan 29Cyclophosphamide 24Bortezomib 23Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5birtamimab 5auricularum 5Whole-Body Irradiation 5Thalidomide 5Mycophenolic Acid 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Busulfan 4sargramostim 3miridesap 3isatuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Immunoglobulin Light-chain Amyloidosis × Blood Component Removal × Clear all
NCT00651937 2020-01-14

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

M.D. Anderson Cancer Center

Phase 2 Completed
80 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT02489500 2018-09-10

VelRand

Boston Medical Center

Phase 3 Terminated
3 enrolled 11 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡